A Randomized, Double-Blind, Placebo-Controlled Phase II Study of VTX-2337 in Combination With Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled Phase II Study of VTX-2337 in Combination With Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 01 May 2017

At a glance

  • Drugs Motolimod (Primary) ; Doxorubicin liposomal
  • Indications Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Therapeutic Use
  • Sponsors VentiRx Pharmaceuticals
  • Most Recent Events

    • 01 May 2017 Results assesing safety and efficacy of addition of motolimod to PLD in intention to treat population and subgroup (patients who experienced injection site reactions) of patients, published in the Annals of Oncology
    • 12 Feb 2017 Primary endpoint (Overall survival (OS) of patients treated with VTX-2337 + PLD versus those treated with PLD alone) has not been met.
    • 12 Feb 2017 Results assessing safety and efficacy of addition of motolimod to PLD treatment, published in the Annals of Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top